WellDoc receives its eleventh FDA 510(k) clearance for its BlueStar system. Credit: Andrey_Popov/Shutterstock

Maryland-based health care and software company, WellDoc has announced it has received an eleventh FDA 510(k) clearance, for its diabetes digital health solution, BlueStar.

A continuous glucose monitoring (CGM)-informed bolus insulin dose calculator has been added to the device and the new clearance will support insulin dosage recommendations based on the patient’s most recent data.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

WelldDoc said the feature will help enhance the platforms coaching abilities to improve patient dietary planning.

WellDoc also stated that the new functionality will support organisations providing diabetes management services.

Dr. Grazia Aleppo, a practicing endocrinologist, with the Feinberg School of Medicine at Northwestern University said: “With this clearance, Welldoc is filling a significant gap for people who require complex insulin regimens. By connecting directly with CGM data and using both glucose values and trend arrows, the BlueStar solution will provide precise and in-the-moment insulin dosing guidance directly to individuals, helping them reach their glucose targets.”.

See Also:

According to Welldoc, they are the first company to receive clearance for a CGM-informed bolus calculator built for adults managing their diabetes with daily injections of insulin.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The firm was also awarded 2023 BIG innovation award in January 2023 for the BlueStar platform.

A report from GlobalData shows that the continuous glucose monitors market value is growing, largely due to the Covid-19 pandemic boosting its popularity. GlobalData forecasts that the continuous glucose monitors market will reach $8.4 billion by 2030.